Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2011 1
2015 1
2017 1
2018 3
2019 1
2020 4
2021 4
2022 4
2023 4
2024 2
2025 5
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
Ellenberger D, Frahm N, Stahmann A, Warnke C, Hellwig K, Kleinschnitz C, Flachenecker P, Mai M, Grothe M, Zettl UK. Ellenberger D, et al. Among authors: kleinschnitz c. J Neurol. 2025 Sep 4;272(9):609. doi: 10.1007/s00415-025-13330-7. J Neurol. 2025. PMID: 40906181
BACKGROUND: High efficacy therapies (HET) play a crucial role in multiple sclerosis (MS) management. HET discontinuation/de-escalation is a critical decision, especially in different age groups, due to potential changes in relapse rates. ...
BACKGROUND: High efficacy therapies (HET) play a crucial role in multiple sclerosis (MS) management. HET discontinuation/de-escalatio …
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Jendretzky KF, Gingele S, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: kleinschnitz c. Autoimmun Rev. 2025 Mar 26;24(4):103754. doi: 10.1016/j.autrev.2025.103754. Epub 2025 Jan 20. Autoimmun Rev. 2025. PMID: 39842533 Free article. Review.
A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical com …
A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental …
Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD.
Häußler V, Trebst C, Engels D, Pellkofer H, Havla J, Duchow A, Schindler P, Schwake C, Pakeerathan T, Fischer K, Ringelstein M, Lindenblatt G, Hümmert MW, Tkachenko D, Bütow F, Giglhuber K, Flaskamp M, Schiffmann I, Korporal-Kuhnke M, Jarius S, Dawin E, Revie L, Senel M, Herfurth M, Walter A, Pompsch M, Kleiter I, Angstwurm K, Kaste M, Grothe M, Wickel J, Rommer PS, Sieb JP, Krämer M, Then Bergh F, Tumani H, Klotz L, Wildemann B, Aktas O, Ayzenberg I, Bellmann-Strobl J, Paul F, Kümpfel T, Friede T, Berthele A, Stellmann JP; Neuromyelitis optica study group (NEMOS). Häußler V, et al. J Neurol Neurosurg Psychiatry. 2025 May 14;96(6):582-592. doi: 10.1136/jnnp-2024-334764. J Neurol Neurosurg Psychiatry. 2025. PMID: 39730197 Free PMC article.
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks.
Schwake C, Ladopoulos T, Häußler V, Kleiter I, Ringelstein M, Aktas O, Kümpfel T, Engels D, Havla J, Hümmert MW, Kretschmer JR, Tkachenko D, Trebst C, Ayroza Galvão Ribeiro Gomes AB, Pröbstel AK, Korporal-Kuhnke M, Wildemann B, Jarius S, Pul R, Pompsch M, Krämer M, Then Bergh F, Gödel C, Schwarz P, Kowarik MC, Rommer PS, Vardakas I, Senel M, Winkelmann A, Retzlaff N, Weber MS, Husseini L, Walter A, Schindler P, Bellmann-Strobl J, Paul F, Gold R, Ayzenberg I; Neuromyelitis Optica Study Group (NEMOS). Schwake C, et al. J Neurol Neurosurg Psychiatry. 2025 Jun 12;96(7):639-646. doi: 10.1136/jnnp-2024-334863. J Neurol Neurosurg Psychiatry. 2025. PMID: 39496464 Free PMC article.
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study).
Passoke S, Stern C, Häußler V, Kümpfel T, Havla J, Engels D, Jarius S, Wildemann B, Korporal-Kuhnke M, Senel M, Stellmann JP, Warnke C, Grothe M, Schülke R, Gingele S, Kretschmer JR, Klotz L, Walter A, Then Bergh F, Aktas O, Ringelstein M, Ayzenberg I, Schwake C, Kleiter I, Sperber PS, Rust R, Schindler P, Bellmann-Strobl J, Paul F, Kopp B, Trebst C, Hümmert MW; Neuromyelitis Optica Study Group (NEMOS). Passoke S, et al. J Neurol Neurosurg Psychiatry. 2025 Mar 13;96(3):296-305. doi: 10.1136/jnnp-2024-333994. J Neurol Neurosurg Psychiatry. 2025. PMID: 39084862 Free PMC article.
Individual cognitive performance was assessed using the Paced Auditory Serial Addition Task (PASAT), the Symbol Digit Modalities Test (SDMT) and the Multiple Sclerosis Inventory Cognition (MuSIC), which are standardised against normative data from healthy controls. Cogniti …
Individual cognitive performance was assessed using the Paced Auditory Serial Addition Task (PASAT), the Symbol Digit Modalities Test (SDMT) …
Correction to: Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jun;271(6):3702-3707. doi: 10.1007/s00415-024-12288-2. J Neurol. 2024. PMID: 38578500 Free PMC article. No abstract available.
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Kümpfel T, et al. J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Epub 2023 Sep 7. J Neurol. 2024. PMID: 37676297 Free PMC article. Review.
[Consensus recommendations on regional interdisciplinary standardization of MRI diagnostics for multiple sclerosis in the metropolitan area of Essen].
Stettner M, Wattjes MP, Krüger K, Pul R, Fleischer M, Achnitz U, Agne H, Bach K, Berkenfeld R, Bongartz U, Brüggemann A, Burgsmüller L, Cohnen J, Deuschl C, Friedrich A, Graziano P, Hackert J, Hapig B, Henkel A, Henrich H, Hükelheim-Görden M, Kratsch L, Kytzia D, Lanzman R, Heusch P, Laufenburg C, Merguet S, Metz U, Montag M, Obeid M, Ornek A, Peters S, Plajer T, Plassmann J, Pump H, Rauchfuss-Hartych B, Reinboldt MP, Seng K, Stauder M, Wettig AK, Wolters A, Yilmam S, Kleinschnitz C. Stettner M, et al. Among authors: kleinschnitz c. Nervenarzt. 2023 Dec;94(12):1123-1128. doi: 10.1007/s00115-023-01531-2. Epub 2023 Aug 18. Nervenarzt. 2023. PMID: 37594495 Free PMC article. Review. German.
Magnetic resonance imaging (MRI) is of exceptional importance in the diagnostics and monitoring of multiple sclerosis (MS); however, a close interdisciplinary cooperation between neurologists in private practice, (neuro)radiological practices, hospitals or specialized MS c …
Magnetic resonance imaging (MRI) is of exceptional importance in the diagnostics and monitoring of multiple sclerosis (MS); however, …
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF, Möhn N, Witte T, Schefzyk M, Wiestler M, Lovric S, Hufendiek K, Schwenkenbecher P, Sühs KW, Friese MA, Klotz L, Pul R, Pawlitzki M, Hagin D, Kleinschnitz C, Meuth SG, Skripuletz T. Konen FF, et al. Among authors: kleinschnitz c. Autoimmun Rev. 2023 May;22(5):103312. doi: 10.1016/j.autrev.2023.103312. Epub 2023 Mar 15. Autoimmun Rev. 2023. PMID: 36924922 Free article. Review.
More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therape …
More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration ( …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
29 results